Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation

Experimental Dermatology

Volumn 18, Issue 12, 2009, Pages 1079-1081

  Dellinger, Anthony ^a   Zhou, Zhiguo ^a   Lenk, Robert ^a   MacFarland, Darren ^a   Kepley, Christopher L ^a  

^a Luna Nanoworks   (United States)

Author keywords

Fullerene; Inflammation; Oxidative stress

Indexed keywords

FULLERENE DERIVATIVE; NANOMATERIAL; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; EAR; EDEMA; LETTER; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; SKIN INFLAMMATION;

ANIMALS; DERMATITIS, CONTACT; EAR AURICLE; EDEMA; FULLERENES; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; NANOSTRUCTURES; TETRADECANOYLPHORBOL ACETATE;

EID: 70849121901     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00904.x     Document Type: Letter

References (23)

1. Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Ann Med 2007, 39:18-27.
2. Moore R A, Derry S, Phillips C J, McQuay H J. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006, 20:7-79.
3. Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 2003, 38:913-923.
4. Djordjevic A, Bogdanovic G, Dobric S. Fullerenes in biomedicine. J BUON 2006, 11:391-404.
5. Bakry R, Vallant R M, Najam-ul-Haq M. Medicinal applications of fullerenes. Int J Nanomed 2007, 2:639-649.
6. Jensen A W, Wilson S R, Schuster D I. Biological applications of fullerenes. Bioorg Med Chem 1996, 4:767-779.
7. Dugan L L, Turetsky D M, Du C. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 1997, 19:9434-9439.
8. Ryan J J, Bateman H R, Stover A. Fullerene nanomaterials inhibit the allergic response. J Immunol 2007, 179:665-672.
9. Foley S, Crowley C, Smaihi M. Cellular localisation of a water-soluble fullerene derivative. Biochem Biophys Res Commun 2002, 294:116-119.
10. Fumelli C, Marconi A, Salvioli S. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2000, 115:835-841.
11. Monti D, Moretti L, Salvioli S. C60 carboxyfullerene exerts a protective activity against oxidative stress-induced apoptosis in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2000, 277:711-717.
12. Chirico F, Fumelli C, Marconi A. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol 2007, 16:429-436.
13. Hannun Y A, Bell R M. Phorbol ester binding and activation of protein kinase C on triton X-100 mixed micelles containing phosphatidylserine. J Biol Chem 1986, 261:9341-9347.
14. Black C A. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol Online J 1999, 5:7.
15. Griswold D E, Martin L D, Badger A M, Breton J, Chabot-Fletcher M. Evaluation of the cutaneous anti-inflammatory activity of azaspiranes. Inflamm Res 1998, 47:56-61.
16. Giannaras A, Selig W, Ellis J, Hullinger T. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol 2005, 506:265-271.
17. Szallasi A, Blumberg P M. Neurogenic component of phorbol ester-induced mouse skin inflammation. Cancer Res 1989, 49:6052-6057.
18. Kavelaars A, Vroon A, Raatgever R P. Increased acute inflammation, leukotriene B4-induced chemotaxis, and signaling in mice deficient for G protein-coupled receptor kinase 6. J Immunol 2003, 171:6128-6134.
19. Galli S J, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008, 49:7-19.
20. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004, 34:785-796.
21. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 2007, 106:S17-S26.
22. Pietsch A, Erl W, Lorenz R L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996, 52:433-439.
23. Wilson S R, Schuster D I, Nuber B, Meier M, Prato M, Taylor R, Kadish K, Ruoff R. Fullerenes: chemistry, physics, and technology 2000, eds, New York, John Wiley & Sons